Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Cyclacel Pharmaceuticals ( (CYCC) ) is now available.
On September 12, 2025, Bio Green Med Solution, Inc. completed the acquisition of Fitters Sdn. Bhd., a Malaysian company specializing in fire safety equipment, through a share exchange agreement. This strategic acquisition diversifies Bio Green Med’s business portfolio, allowing it to explore opportunities in both the fire protection and pharmaceutical sectors, and positions the company to create long-term value for its shareholders.
Spark’s Take on CYCC Stock
According to Spark, TipRanks’ AI Analyst, CYCC is a Underperform.
Cyclacel Pharmaceuticals is currently under significant financial strain, marked by operational inefficiencies and a weak financial position, as reflected in its low financial performance score. While the technical indicators suggest a neutral trend, the valuation is unattractive due to its negative P/E ratio and lack of dividend yield. These factors collectively result in a low overall stock score.
To see Spark’s full report on CYCC stock, click here.
More about Cyclacel Pharmaceuticals
Bio Green Med Solution, Inc., formerly Cyclacel Pharmaceuticals, Inc., is a diversified company engaged in the fire protection and biopharmaceutical industries. The company has expanded its business portfolio by integrating Fitters Sdn. Bhd., a Malaysia-based group specializing in fire protection products and services. Headquartered in Malaysia, Bio Green Med Solution focuses on advancing opportunities across these distinct sectors while maintaining its commitment to long-term value creation for shareholders.
Average Trading Volume: 1,863,967
Technical Sentiment Signal: Strong Sell
Current Market Cap: $14.25M
See more data about CYCC stock on TipRanks’ Stock Analysis page.